P-ISSN 2587-2400 | E-ISSN 2587-196X
EJMO Volume : 8 Issue : 3 Year : 2024
COVID-19 in EJMO 8/3EJMO Current Issue EJMO Archive Most Cited Articles Ahead of Print Most Accessed Articles
Copyright Transfer Form
ICMJE COI Form

Published Issues

WEB OF SCIENCE click

  • Impact Factor: 0.8

  • Medicine, General & Internal: Q2 146/322


    • SCOPUS click

  • CiteScoreTracker 2023: 5.6
  • CiteScore year 2022: 0.9
  • CiteScore year 2021: 0.2


    • Volume: 8

    1-1122024 Issue: 1 113-2342024 Issue: 2 235-3822024 Issue: 3

    Volume: 7

    1-882023 Issue: 1 95-1992023 Issue: 2 201-2882023 Issue: 3 289-4142023 Issue: 4

    Volume: 6

    1-932022 Issue: 1 95-1932022 Issue: 2 195-2702022 Issue: 3 271-3802022 Issue: 4

    Volume: 5

    1-932021 Issue: 1 94-2002021 Issue: 2 201-2802021 Issue: 3 281-3662021 Issue: 4

    Volume: 4

    1-1052020 Issue: 1 107-1812020 Issue: 2 181-2632020 Issue: 3 265-3452020 Issue: 4

    Volume: 3

    1-752019 Issue: 177-1532019 Issue: 2155-2352019 Issue: 3236-3062019 Issue: 4

    Volume: 2

    1-542018 Issue: 155-1192018 Issue: 2121-1872018 Issue: 3189-2602018 Issue: 4

    Volume: Supplement 2

    1-78Abstracts of the 3th National Immunotherapy and Oncology Congress 2019

    Volume: Supplement 1

    1-48Abstracts of the 2th National Immunotherapy and Oncology Congress 2018

    Volume: 1

    1-542017 Issue: 155-1172017 Issue: 2119-1822017 Issue: 3183-2432017 Issue: 4



    EJMO & Congress of Oncology and immunotherapy association

    Pictures from Congress and EJMO printed version

    To see Abstracts of Oncology and immunotherapy association 2019 Congress

    To see Abstracts of Oncology and immunotherapy association 2018 Congress

    Submit Manuscript
    WEB OF SCÝENCE click

  • Impact Factor: 0.8

  • Medicine, General & Internal: Q2 146/322


    • SCOPUS click

  • CiteScoreTracker 2023: 5.6
  • CiteScore year 2021:
    0.9
  • CiteScore year 2021:
    0.2


    • Google Scholar click

  • Number of Articles:315
  • Citations:2587
  • h-index:16
  • i10-index:=26

  • EJMO NLM ID: 101720527

  • Accept Ratio :18.2 %
  • Final decision avg 34 day


    • Copyright © 2020 Eurasian Journal of Medicine and Oncology, EJMO

    EJMO & EJMO